News Story: Full Text
Sponsored By
Cleveland Clinic Brain Tumor and Neuro-Oncology Center
Please Click On The Above Banner For More Details
Braintumor Website


Advectus Life Sciences Inc. - Pre-clinical brain cancer collaboration

Posted on: 06/03/2002

Press Release
SOURCE: Advectus Life Sciences Inc.

Advectus Life Sciences Inc. - Pre-clinical brain cancer collaboration

VANCOUVER, June 3 /CNW/ - Advectus Life Sciences Inc.
( announced today that it has entered into a Collaboration Agreement with the University of North Carolina at Chapel Hill (UNC-CH) to determine the efficacy of its patented nanoparticle based technology (Nanocure(TM)) for the delivery of cancer fighting drugs across the blood-brain barrier for the treatment of brain tumors. The efficacy of the Nanocure(TM) formulation (P80DOX-NP) will be tested on rodent brain metastases arising from lung carcinoma (2), breast carcinoma, melanoma, renal cell carcinoma, and colon carcinoma. Study design will be randomized, placebo- controlled studies measuring survival as a surrogate for intracranial tumor progression/regression.

P80DOX-NP is a novel delivery method for doxorubicin that crosses the blood-brain barrier. This series of pre-clinical studies will test the responsiveness of tumors in the brain to this compound. Successful demonstration of an antitumor effect could serve as a basis for a clinical trial using P80DOX-NP to treat the large group of patients with brain metastases. The study is designed to lead into Phase I Clinical Trials.

The mission of the University of North Carolina Brain Tumor Center is to lead the fight against brain tumors by providing patients with access to the best and most current therapies. UNC-CH collaborates closely with other brain tumor centers to find new treatments and make those new treatments available to all patients as soon as possible. UNC-CH welcomes the opportunity to work with colleagues at other institutions in order to advance the battle against brain tumors.

Advectus Life Sciences Inc. (AVX:TSX VENTURE) is a development stage company focused on the development and commercialization of a patented process using nanotechnology for the delivery of approved cancer fighting drugs across the blood-brain barrier for the treatment of brain tumors. For more information about Advectus Life Sciences, visit
Click HERE to return to brain tumor news headlines

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557